Novartis Ag

Xingnian Fu

Yuan Mi

Zhengtian Yu

Ji Yue Zhang

Yue Ping Li

Feng He

Lei Liu

Guoliang Xun

Miao Dai

Yao-Chang Xu

Ling Li

Martin Sendzik

Lei Li

Qiong Zhang

Lei Jiang

Long Wang

Wei Qi

Hailong Zhang

Fang Liang

Xiang-Ju Justin Gu

Man Zhang

Ho Man Chan

Yongfeng Sun

Kehao Zhao

Xiaoxia Yan

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R, Rand Rare as defined herein.

Triazolopyridine compounds and uses thereof

A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R, R, R, and Rare as defined herein.

Imidazolepyridine compounds and uses thereof

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Heterocyclic oxime compounds

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I). 

Heterocyclic hydrazone compounds

Growing community of inventors

Lanzhou, China

Xingnian Fu